|Other Names||GTPase NRas, Transforming protein N-Ras, NRAS, HRAS1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP7745a was selected from the N-term region of human NRAS. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.|
|Cellular Location||Cell membrane; Lipid-anchor; Cytoplasmic side. Golgi apparatus membrane; Lipid-anchor. Note=Shuttles between the plasma membrane and the Golgi apparatus|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
NRAS is a membrane protein that shuttles between the Golgi apparatus and the plasma membrane. This shuttling is regulated through palmitoylation and depalmitoylation by the ZDHHC9-GOLGA7 complex. This protein, which has intrinsic GTPase activity, is activated to a GTP-bound form by a GTPase activating protein and inactivated to a GDP-bound form by a guanine nucleotide-exchange factor. Defects in the gene encoding this protein are a cause of juvenile myelomonocytic leukemia (JMML).
Smalley,K.S., Cancer Res. 68 (14), 5743-5752 (2008)Banerji,U., Mol. Cancer Ther. 7 (4), 737-739 (2008)
If you have any additional inquiries please email technical services at email@example.com.